SCHEMBL2954053

SCHEMBL2954053

CCOC(=O)c1sc2c(ccc(=O)n2-c2ccccc2)c1Nc1ccc(Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 2/20 0.50
FNTA P49354 2/20 0.46
FNTB P49356 2/20 0.46
ALDH1A1 P00352 4/20 0.46
MAPT P10636 6/20 0.45
P2RX3 P56373 1/20 0.44
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
NPSR1 Q6W5P4 2/20 0.43
HTT P42858 3/20 0.42
NPC1 O15118 2/20 0.42
HPGD P15428 2/20 0.42
RAB9A P51151 2/20 0.42
ACHE P22303 1/20 0.42
LMNA P02545 2/20 0.41
MCL1 Q07820 1/20 0.41
GABRA2 P47869 1/20 0.41
GABRB2 P47870 1/20 0.41
GAA P10253 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1266606 0.93 MAPT (0.49) DHODHFNTAFNTBALDH1A1MAPT
SCHEMBL2958676 0.90 ALDH1A1 (0.47) DHODHFNTAFNTBALDH1A1MAPT
SCHEMBL2952196 0.90 MAPT (0.52) DHODHALDH1A1MAPTP2RX3MEN1
SCHEMBL1266134 0.89 DHODH (0.44) DHODHALDH1A1MAPTP2RX3MEN1
SCHEMBL2960362 0.88 FNTA (0.48) DHODHFNTAFNTBALDH1A1MAPT
SCHEMBL1267006 0.87 DHODH (0.44) DHODHALDH1A1MAPTMEN1KMT2A
SCHEMBL1266639 0.86 MAPT (0.51) ALDH1A1MAPTMEN1KMT2AHTT
SCHEMBL1266180 0.86 ALDH1A1 (0.45) DHODHFNTAFNTBALDH1A1MAPT
SCHEMBL2953098 0.85 MAPT (0.46) DHODHFNTAFNTBALDH1A1MAPT
SCHEMBL2955536 0.85 FNTA (0.44) DHODHFNTAFNTBALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US claimed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US claimed
US-7763729-B2 Bicyclic heteroaromatic derivatives UCB PHARMA S.A. (BE) 2010-07-27 US disclosed
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives CELLTECH R&D LIMITED (GB) 2009-02-12 US disclosed
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US disclosed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors MAPK1, CNKSR1, ALK DHODH 3134/4885FNTA 3289/4885FNTB 1417/4885
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives MAPK1, CNKSR1, CBR1 DHODH 3227/4885FNTA 3146/4885FNTB 1138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.